The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Psimei Pharmaceuticals aims to improve the outcome of conventional radiotherapy for cancer patients by applying its Photon Activation Therapy (PAT) and Boron Neutron Capture Therapy (BNCT) technologies. The UK start-up has so far raised one million pounds since it was founded in January 2001.

The discoveries of the platelet-inhibiting antibody, ReoPro, and PerioStat, a formulation of doxycycline, put SUNY-Stony Brook on the tech transfer map. It is now working with start-ups, too.